Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheim...
September 29 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
the publication of peer-reviewed data demonstrating the ability of
its lead candidate, ANVS401, also known as Posiphen, to improve
axonal transport, the information highway of nerve cells. The
publication, “Targeting increased levels of APP in Down syndrome:
Posiphen-mediated reductions in APP and its products reverse
endosomal phenotypes in the Ts65Dn mouse model,” was published in
Alzheimer’s & Dementia: The Journal of the Alzheimer’s
Association. The study was conducted at the University of
California San Diego’s Department of Neurosciences in Dr. William
Mobley's lab at UCSD. Professor Mobley, MD, PhD. is Distinguished
Professor, Department of Neurosciences, and the Florence Riford
Chair for Alzheimer's Research. He is an expert on Down Syndrome
and axonal transport.
Alzheimer's Disease and Down Syndrome share
several characteristics, including high levels of neurotoxic
proteins; specifically, amyloid precursor protein (APP), its
C-terminal fragment, phospho-tau and alpha-synuclein. High levels
of these proteins impair the transport of vesicles carrying
neurotrophic factors. The resulting AD pathology is driven by
compromised transport of neurotrophic signals. Treatment of Down
Syndrome mice with ANVS401 normalized levels of neurotoxic proteins
and reversed deficits in axonal transport, regulated brain
homeostasis, lowered inflammation, and normalized mouse
behavior.
“This is another important step forward for our
unique approach to treating neurodegeneration, and we are thrilled
to have our manuscript published in the very prestigious journal
Alzheimer’s & Dementia,” commented Maria Maccecchini, Ph.D.,
Founder and CEO of Annovis Bio. “This paper supports the basic
hypothesis of the efficacy of our drug. ANVS401 lowered levels of
neurotoxic proteins, normalized axonal transport, lowered
inflammation, and led to normal mouse behavior. We are very
thankful to Professor Mobley for his help, support, and work in
demonstrating the importance of axonal transport in
neurodegenerative diseases. The study proved that our drug
normalized axonal transport in nerve cells in the brain and body of
mice. This is highly significant as it adds to our body of data
that shows our lead compound is the only drug to improve axonal
transport, the information highway of the nerve cell, by attacking
multiple neurotoxic proteins."
Annovis is currently conducting a Phase 2a study
of ANVS401 in early AD and PD patients. The study compares in both
patient populations how nerve cells die by measuring all the steps
in the toxic cascade leading to nerve cell death and how ANVS401
might reverse the toxic cascade and recover normal brain
function. In addition to target and pathway engagement, the
Phase 2 study will also examine safety and tolerability as well as
the effect of ANVS401 on motor impairment and non-motor symptoms in
early PD patients and the effect on memory and cognitive
function in early AD subjects.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate, including that
clinical trials may be delayed. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Sep 2023 to Sep 2024